New drug duo takes on rare, deadly lymphoma

NCT ID NCT06863402

Recruiting now Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase II trial tests whether combining nemtabrutinib (a targeted drug) with pembrolizumab (an immunotherapy) can shrink tumors in 32 people with Richter transformation, an aggressive lymphoma that arises from chronic lymphocytic leukemia. Participants must have failed or be unable to take standard chemotherapy. The study measures how many patients respond and tracks quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nemtabrutinib and pembrolizumab
What this could lead to: If successful, this combination could offer a new treatment option for patients with Richter transformation, a rare and aggressive lymphoma that is hard to treat.
What could go wrong: This is a small, early-phase trial (32 people) with no control group. The drugs may cause side effects like fatigue or immune reactions, and the response rate may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA RICHTER SYNDROME

Contacts and locations

Locations

Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.